Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

HA-Coated PLGA Nanoparticles Loaded with Apigenin for Colon Cancer with High Expression of CD44

Version 1 : Received: 5 October 2023 / Approved: 5 October 2023 / Online: 5 October 2023 (14:22:23 CEST)

A peer-reviewed article of this Preprint also exists.

Yang, B.; Mao, Y.; Zhang, Y.; Hao, Y.; Guo, M.; Li, B.; Peng, H. HA-Coated PLGA Nanoparticles Loaded with Apigenin for Colon Cancer with High Expression of CD44. Molecules 2023, 28, 7565. Yang, B.; Mao, Y.; Zhang, Y.; Hao, Y.; Guo, M.; Li, B.; Peng, H. HA-Coated PLGA Nanoparticles Loaded with Apigenin for Colon Cancer with High Expression of CD44. Molecules 2023, 28, 7565.

Abstract

Apigenin (API) possesses excellent antitumor properties, but its limited water solubility and low bioavailability restrict its therapeutic impact. Thus, a suitable delivery systems is needed to overcome these limitations and improve the therapeutic efficiency. Poly (lactic-co-glycolic acid) (PLGA) is a copolymer extensively utilized in drug delivery. Hyaluronic acid (HA) is a major extracellular matrix and can specifically bind with CD44 on colon cancer cells. Chitosan (CS) can serve as an intermediate binding with HA and PLGA. Herein, we aimed to perpare receptor-selective HA-coated PLGA nanoparticles (NPs) for colon cancer with high expression of CD44. Firstly, API was encapsulated in PLGA to obtain PLGA-API-NPs, which were then sequentially combined with CS and HA to form HA-coated PLGA NPs. HA coated PLGA NPs had a stronger sustained-release capability. Cellular uptake of HA coated PLGA NPs was enhanced in HT-29 cells with high expression of CD44. HA-PLGA-DiR-NPs can target specificity towards the HT-29 ectopic tumor model. Overall, HA coated PLGA NPs was an effectively drug deliver platform for API in treatment of colon cancer with high expression of CD44.

Keywords

API; PLGA nanoparticles; HA; CD44; colon cancer; targeted delivery

Subject

Medicine and Pharmacology, Pharmacy

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.